BioMarin Pharmaceutical Files 13F Amid Stock Rating Upgrade
What happened
BioMarin Pharmaceutical filed a Form 13F with the Securities and Exchange Commission. This filing occurred as William P. Blair upgraded the company's stock rating. Separately, Profund Advisors LLC increased its stake in BioMarin Pharmaceutical by 34.3% during the third quarter, according to its recent filing with the SEC.
From dailypolitical.com
Why it matters
The increased buying activity by institutional investors, including Primecap Management Co. CA and Dimensional Fund Advisors LP, suggests growing confidence in BioMarin Pharmaceutical. This activity, combined with the stock rating upgrade by William P. Blair, may influence market demand for the company's shares.
From dailypolitical.com
Who's involved
- BioMarin PharmaceuticalThe biotechnology company that filed the 13F.
- Securities and Exchange CommissionThe government agency overseeing mandatory regulatory filings.
- William P. BlairThe individual who upgraded the stock rating for BioMarin Pharmaceutical.
Keep exploring
The entities involved
-
BioMarin Pharmaceutical
American company
-
Securities and Exchange Commission
government agency of the Philippines
-
William P. Blair
American astrophysicist
Related events
- NewLake Capital Partners, Inc. filed Form 13F with the Securities and Exchange Commission.
- Vontobel filed Form 13F with the Securities and Exchange Commission on October 20, 2026.
- Leonard Rickey Investment Advisors P.L.L.C. filed its required 13F report with the Securities and Exchange Commission.
- Horace Mann Educators Corporation filed a Form 13F with the SEC and received analyst reports.
- Verus Financial Partners Inc. filed its required 13F report with the Securities and Exchange Commission on November 1, 2026.